USA-based Isis Pharmaceuticals (Nasdaq:ISIS) has earned a $1 million milestone payment from UK pharma giant GlaxoSmithKline (LSE: GSK) related to the initiation of an open-label extension study of ISIS-TTR(Rx), which is being offered to those patients with familial amyloid polyneuropathy (FAP) who have completed dosing in the Phase II/III study of ISIS-TTR(Rx). ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) stock opened at $53.25 in last session, and closed at $55.41, while the day range of ISSI stock is $53.10-$55.97.The stock showed a negative weekly performance of -4.40%.
Zogenix Inc. (NASDAQ: ZGNX) is a top name to buy at Oppenheimer and Leerink Swann for 2014. The FDA approved its top new drug Zohydro. The drug is a timed-release form of hydrocodone, which is one of the most highly prescribed pain medications in the world. The Zogenix drug contains no acetaminophen, which has been proven to cause liver damage. This is a boon to patients suffering from oncology related pain, as often radiation therapy weakens or damages the liver. The company also has a migraine headache treatment called Sumavel that is very popular and is gaining in acceptance among physicians. Zogenix, Inc. (NASDAQ:ZGNX) stock opened at $4.30, in last session and closed at $4.53, by gained 6.59%. The 52 week range was $1.25-$5.19.Company’s market capitalization is $627.10 million.
Neurocrine Biosciences (NASDAQ:NBIX) saw some unusual options trading on Tuesday. Investors acquired 3,590 put options on the stock,Stock Ratings Network.com reports. This represents an increase of approximately 430% compared to the typical volume of 677 put options Neurocrine Biosciences, Inc. (NASDAQ:NBIX) stock gained 6.90% and finished the last session at $17.82.The EPS of the stock remained -0.69.Company’s market capitalization is $1.34 billion.
Halozyme Therapeutics (NASDAQ:HALO) released its earnings data on Thursday. The company reported ($0.19) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.17) by $0.02, American Banking News.com reports. The company had revenue of $12.50 million for the quarter, compared to the consensus estimate of $21.80 million. During the same quarter in the prior year, the company posted ($0.04) earnings per share. The company’s quarterly revenue was down 42.7% on a year-over-year basis. Halozyme Therapeutics, Inc. (NASDAQ:HALO) stock opened the session at $14.09, and closed the session at $14.97.The 52 week range of the HALO stock remained $5.03-$18.18 and the day range was $14.09-$15.00.